Consolidating Plant Medicine, Permaculture and Indigenous Wisdom With Colette Condorcita, Decriminalize Philadelphia

Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.

We will cover the very real risks involved in investing in MindMed such as:
1. The possibility of MindMed’s medicines being inefficacious
– Whether of not MMED’s clinical trials succeed
2.MindMed’s incertain long term profitability
– Can the company scale production and training protocols?
3.MindMed Stock volatility
– MindMed’s market cap
– Future short interests

MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)

MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own

Donate to MAPS: https://maps.org/about-maps/our-team/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

In today’s episode of Psychedelic Spotlight Podcast, James Hallifax from The Psychedelic Investor, had the pleasure of interviewing Rick Doblin, founder of MAPS. When it comes to psychedelic research, the questions of whether psychedelics can help with mental health, and the de-stigmatization of psychedelics, Rick Doblin is the certified G.O.A.T.

Can MDMA treat PTSD? Rick Doblin (and the science) says YES!

Should psychedelics be legalized? Rick Doblin (and facts and logic) say YES!

Did MDMA save the world from World War III? Rick Doblin says… okay well probably not. But it may have played a role!

To learn more about MAPS and their clinical trial, visit maps.org
While you are there, if you are feeling generous and want to donate to a good cause, MAPS is a charity.

Links:
MDMA and the Soviets
https://thebulletin.org/2021/12/psychedelics-the-newest-tool-in-nuclear-negotiations/

CBS MDMA for Veterans Interview
https://www.cbsnews.com/news/mdma-ecstasy-psychedelics-treating-veterans-ptsd/

Today Show MDMA for Veterans Interview
https://www.today.com/health/mdma-ptsd-study-veteran-shares-experience-rcna4495

#RickDoblin #MDMA #PSYCHEDELICS

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/

Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

Back to the potential MindMed, Compass Pathways & atai merger that Kevin O
Leary speculates on…

Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?

The “Shark Tank” star predicts three of the biggest psychedelic companies will merge into a mega-corporation, but our resident Psychedelic Investor wonders: Should they?

Famed investor Kevin O’Leary made a bold prediction last Tuesday, saying that psychedelic companies MindMed, atai Life Sciences and Compass Pathways will merge. For psychedelic stock investors, this would be a tsunami-sized event that would have ripple effects throughout the industry.

The Shark Tank star made the comments at the inaugural Benzinga Psychedelics Capital Conference in Miami, arguing that the companies “each need another $200 million by the time they get this to medicine.” In other words, as I have written before, the psychedelic medicines industry is heavily capital intensive, and getting multiple drugs from pre-clinical trials through Phase 3 trials and approved by the FDA can cost hundreds of millions of dollars.

Even though these companies are three of the best-financed in the industry — atai (Nasdaq: atai) has $362 million, Compass (Nasdaq: CMPS) has $273 million and MindMed (Nasdaq: MNMD, NEO: MMED) has $133 million — the celebrity investor believes that in order to succeed the companies may have to become one.

Read the entire article here: https://psychedelicspotlight.com/kevin-oleary-predicts-3-biggest-psychedelic-companies-will-merge-atai-mindmed-compass-pathways/

One man claims magic mushrooms healed his lost sense of smell. Read the full story here.
https://whyy.org/segments/could-magic-mushrooms-cure-covid-related-smell-loss/

A new anti-depressant study is out. Read the full study here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265928#sec011

#Mindmed #kevinoleary #psychedelicstocks

MindMed has officially been added to the NASDAQ Global Market.
On April 22nd, MindMed filed an 8-A12B with the SEC which ultimately allowed it to uplist to the NASDAQ. For NEO owners, the ticker symbol will remain MMED, for OTC owners, it’ll change to MNMD.

On 23rd of April, MindMed announced that as onf April 27th MindMed will be trading as MNMD on the NASDAQ. This means that MindMed was able to meet financial and listing requirements. Typically when securities get listed on major stock exchanges, they are highly traded and prices higher than those that trade OTC. Being able to uplist and trade on an exchange such as the NASDAQ will provide MindMed exposure and visibility to a larger market which might, in the short term, 2, 3 or 4x MindMed’s stock price as more people buy the stock due to FOMO. This happened when Compass Pathways IPOed which almost 4xed its share price within a few days from $17 to $60 before CMPS dropped back down to $33.

Where does MindMed go from here on? MMEDF is just at the beginning of their long-term growth trajectory. Some investors might feel inclined to take profits, which is absolutely understandable. However, like I’ve been saying in the majority of my MindMed episodes or any psychedelic stock videos, the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedNasdaq #MindMedstock